Histologic transformation in marginal zone lymphomas

Annals of Oncology

Volumn 26, Issue 11, 2015, Pages 2329-2335

  Conconi, Annarita ^a,b   Franceschetti, S ^a   Aprile von Hohenstaufen, K ^c   Margiotta Casaluci, G ^a   Stathis, A ^c   Moccia, A A ^c   Bertoni, F ^c,d   Ramponi, A ^e   Mazzucchelli, L ^f   Cavalli, F ^c   Gaidano, G ^a   Zucca, E ^c  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b OSPEDALE DEGLI INFERMI   (Italy)

^c ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^d INSTITUTE OF ONCOLOGY RESEARCH   (Switzerland)

^e Institute of Medicine   (Italy)

^f Institute for Pathology   (Switzerland)

Author keywords

histologic transformation; Marginal zone lymphoma; risk factors

Indexed keywords

LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CAUSAL ATTRIBUTION; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HISTOLOGIC TRANSFORMATION; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPHOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MARGINAL ZONE LYMPHOMA; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK ASSESSMENT; SURVIVAL RATE; COHORT ANALYSIS; LYMPHOMA, B-CELL, MARGINAL ZONE; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; TRENDS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84947763334     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv368     Document Type: Article

References (29)

1. Isaacson PG, Chott A, Nakamura S et al. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In Swerdlow S, Campo E, Harris NL et al. (eds), WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC 2008; 214-217.
2. Isaacson PG, Piris MA, Berger F et al. Splenic B-cell marginal zone lymphoma. In Swerdlow S, Campo E, Harris NL et al. (eds), WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC 2008; 185-187.
3. Campo E, Pileri SA, Jaffe ES et al. Nodal marginal zone B-cell lymphoma. In Swerdlow S, Campo E, Harris NL et al. (eds), WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC 2008; 218-219.
4. Traverse-Glehen A, Bertoni F, Thieblemont C et al. Nodal marginal zone B-cell lymphoma: a diagnostic and therapeutic dilemma. Oncology (Williston Park) 2012; 26: 92-99, 103-104.
5. Thieblemont C, Davi F, Noguera ME et al. Splenic marginal zone lymphoma: current knowledge and future directions. Oncology (Williston Park) 2012; 26: 194-202.
6. Bertoni F, Coiffier B, Salles G et al. MALT lymphomas: pathogenesis can drive treatment. Oncology (Williston Park) 2011; 25: 1134-1142, 1147.
7. Meyer AH, Stroux A, Lerch K et al. Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphoma. Ann Oncol 2014; 25: 210-215.
8. Olszewski AJ, Castillo JJ. Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database. Cancer 2013; 119: 629-638.
9. Montalban C, Abraira V, Arcaini L et al. Risk stratification for splenic marginal zone lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases. Br J Haematol 2012; 159: 164-171.
10. Zucca E, Bertoni F, Stathis A, Cavalli F. Marginal zone lymphomas. Hematol Oncol Clin North Am 2008; 22: 883-901, viii.
11. Montoto S, Fitzgibbon J. Transformation of indolent B-cell lymphomas. J Clin Oncol 2011; 29: 1827-1834.
12. Conconi A, Ponzio C, Lobetti-Bodoni C et al. Incidence, risk factors and outcome of histological transformation in follicular lymphoma. Br J Haematol 2012; 157: 188-196.
13. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
14. Xochelli A, Kalpadakis C, Gardiner A et al. Clonal B-cell lymphocytosis exhibiting immunophenotypic features consistent with a marginal-zone origin: is this a distinct entity? Blood 2014; 123: 1199-1206.
15. Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586.
16. Altman DG, De Stavola BL, Love SB, Stepniewska KA. Review of survival analyses published in cancer journals. Br J Cancer 1995; 72: 511-518.
17. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-994.
18. Conconi A, Motta M, Bertoni F et al. Patterns of survival of follicular lymphomas at a single institution through three decades. Leuk Lymphoma 2010; 51: 1028-1034.
19. Camacho FI, Mollejo M, Mateo MS et al. Progression to large B-cell lymphoma in splenic marginal zone lymphoma: a description of a series of 12 cases. Am J Surg Pathol 2001; 25: 1268-1276.
20. Parry-Jones N, Matutes E, Gruszka-Westwood AM et al. Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients. Br J Haematol 2003; 120: 759-764.
21. Dungarwalla M, Appiah-Cubi S, Kulkarni S et al. High-grade transformation in splenic marginal zone lymphoma with circulating villous lymphocytes: the site of transformation influences response to therapy and prognosis. Br J Haematol 2008; 143: 71-74.
22. Arribas AJ, Rinaldi A, Mensah AA et al. DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. Blood 2015; 125: 1922-1931.
23. Zucca E, Conconi A, Laszlo D et al. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginalzone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study. J Clin Oncol 2013; 31: 565-572.
24. Montoto S, Davies AJ, Matthews J et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 2007; 25: 2426-2433.
25. Rossi D, Cerri M, Capello D et al. Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. Br J Haematol 2008; 142: 202-215.
26. Tsimberidou AM, O'Brien S, Khouri I et al. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol 2006; 24: 2343-2351.
27. Ponzoni M, Ghia P. Clonal B-cell lymphocytosis: a new member? Blood 2014; 123: 1118-1119.
28. Casulo C, Burack WR, Friedberg JW. Transformed follicular non-Hodgkin lymphoma. Blood 2015; 125: 40-47.
29. Rossi D. Molecular pathogenesis of transformed lymphomas. Hematol Oncol 2015; 33: 70-74.